Melpomeni Fani

Publication Activity (10 Years)

Years Active: 2019-2023
Publications (10 Years): 8

Top Topics

Neuroendocrine Tumors

Positron Emission Tomography

Randomized Controlled Trial

Top Venues

EJNMMI research

Journal of labelled compounds & radiopharmaceuticals

This page only lists publications with an associated author ORCID identifier.

Publications

Doroteja Novak, Barbara Janota, Anton Amadeus Hörmann, Agnieszka Sawicka, Marko Kroselj, Alicja Hubalewska-Dydejczyk, Melpomeni Fani, Renata Mikolajczak, Petra Kolenc, Clemens Decristoforo, Piotr Garnuszek
Development of the 99m Tc-Labelled SST 2 Antagonist TECANT-1 for a First-in-Man Multicentre Clinical Study. Pharmaceutics 15 (3) (2023)
Jacopo Millul, Lennart Koepke, Gaonkar Raghuvir Haridas, Konstantin M J Sparrer, Rosalba Mansi, Melpomeni Fani
Head-to-head comparison of different classes of FAP radioligands designed to increase tumor residence time: monomer, dimer, albumin binders, and small molecules vs peptides. European journal of nuclear medicine and molecular imaging (2023)
Doroteja Novak, Barbara Janota, Anton Amadeus Hörmann, Agnieszka Sawicka, Marko Kroselj, Alicja Hubalewska-Dydejczyk, Melpomeni Fani, Renata Mikolajczak, Petra Kolenc, Clemens Decristoforo, Piotr Garnuszek
Development of the 99m Tc-Labelled SST 2 Antagonist TECANT-1 for a First-in-Man Multicentre Clinical Study. Pharmaceutics 15 (3) (2023)
Doroteja Novak, Barbara Janota, Anton Amadeus Hörmann, Agnieszka Sawicka, Marko Kroselj, Alicja Hubalewska-Dydejczyk, Melpomeni Fani, Renata Mikolajczak, Petra Kolenc, Clemens Decristoforo, Piotr Garnuszek
Development of the 99m Tc-Labelled SST 2 Antagonist TECANT-1 for a First-in-Man Multicentre Clinical Study. Pharmaceutics 15 (3) (2023)
Melpomeni Fani, Rosalba Mansi, Guillaume P Nicolas, Damian Wild
Radiolabeled Somatostatin Analogs-A Continuously Evolving Class of Radiopharmaceuticals. Cancers 14 (5) (2022)
Rosalba Mansi, Pascale Plas, Georges Vauquelin, Melpomeni Fani
Distinct In Vitro Binding Profile of the Somatostatin Receptor Subtype 2 Antagonist [ 177 Lu]Lu-OPS201 Compared to the Agonist [ 177 Lu]Lu-DOTA-TATE. Pharmaceuticals (Basel, Switzerland) 14 (12) (2021)
Rosalba Mansi, Karim Abid, Guillaume P Nicolas, Luigi Del Pozzo, Eric Grouzmann, Melpomeni Fani
A new 68Ga-labeled somatostatin analog containing two iodo-amino acids for dual somatostatin receptor subtype 2 and 5 targeting. EJNMMI research 10 (1) (2020)
Rosalba Mansi, Melpomeni Fani
Design and development of the theranostic pair 177 Lu-OPS201/68 Ga-OPS202 for targeting somatostatin receptor expressing tumors. Journal of labelled compounds & radiopharmaceuticals 62 (10) (2019)